Advanced search
Publication Cover
OncoTargets and Therapy Volume 17, 2024 - Issue
Submit an article Journal homepage
104
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Response to Savolitinib in a Patient with Advanced Poorly Differentiated Lung Carcinoma Positive for a Novel EML4-MET Gene Fusion

Ganlu Ouyang1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China;2 Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-1375-5560View further author information
ORCID Icon,
Pei Shu3 Devision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China;4 Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Yinyin Xue1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China;2 Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
,
Feng Luo1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China;2 Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaView further author information
&
Yan Li1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China;2 Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 79-84 | Received 30 Sep 2023, Accepted 17 Jan 2024, Published online: 29 Jan 2024

References

  • Zhuo M, Liang Z, Yi Y, et al. Analysis of MET kinase domain rearrangement in NSCLC. Lung Cancer. 2020;145:140–143. doi:10.1016/j.lungcan.2020.04.040
  • Liu J, Shen L, Qian Y, Liu Y, Su M, Yi L. Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report. Transl Cancer Res. 2022;11(8):2931–2935. doi:10.21037/tcr-22-141
  • Ai X, Yu Y, Zhao J, et al. Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting. Therapeut Adv Med Oncol. 2022;14:17588359221112474. doi:10.1177/17588359221112474
  • Blanc-Durand F, Alameddine R, Iafrate AJ, et al. Tepotinib efficacy in a patient with non-small cell lung cancer with brain metastasis harboring an HLA-DRB1-MET gene fusion. Oncologist. 2020;25(11):916–920. doi:10.1634/theoncologist.2020-0502
  • Ma Q, Kong L, Zhong D. Case report: dramatic response to crizotinib in a patient with non-small cell lung cancer positive for a novel ARL1-MET fusion. Front Oncol. 2022;12:804330. doi:10.3389/fonc.2022.804330
  • Markham A. Savolitinib: first Approval. Drugs. 2021;81(14):1665–1670. doi:10.1007/s40265-021-01584-0
  • Zhu X, Lu Y, Lu S. Landscape of savolitinib development for the treatment of non-small cell lung cancer with MET alteration-A narrative review. Cancers. 2022;14(24). doi:10.3390/cancers14246122
  • Lu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, Phase 2 study. Lancet Respir Med. 2021;9(10):1154–1164. doi:10.1016/S2213-2600(21)00084-9
  • Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373–386. doi:10.1016/S1470-2045(19)30785-5
  • Zhu YC, Wang WX, Xu CW, et al. Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing. Ann Oncol. 2018;29(12):2392–2393. doi:10.1093/annonc/mdy455
  • Zhu YC, Wang WX, Song ZB, et al. MET-UBE2H fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma. J Thorac Oncol. 2018;13(10):e202–e204. doi:10.1016/j.jtho.2018.05.009
  • Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5(1):4846. doi:10.1038/ncomms5846
  • Sun D, Wu W, Wang L, et al. Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer. J Transl Med. 2023;21(1):150. doi:10.1186/s12967-023-03999-7
  • Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discovery. 2020;10(6):783–791. doi:10.1158/2159-8290.CD-20-0422
  • Aapro M, Lyman GH, Bokemeyer C, et al. Supportive care in patients with cancer during the COVID-19 pandemic. ESMO open. 2021;6(1):100038. doi:10.1016/j.esmoop.2020.100038
  • de Joode K, Dumoulin DW, Tol J, et al. Dutch Oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer. 2020;141:171–184. doi:10.1016/j.ejca.2020.09.027

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.